Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody therapeutics - Numab/Intarcia

Next Previous
Drug Profile

Research programme: antibody therapeutics - Numab/Intarcia

Alternative Names: Autoimmune disorders therapeutics - Numab/Intarcia; Diabetes therapeutics - Numab/Intarcia; ND 003; ND 007; ND 016; Obesity therapeutics - Numab/Intarcia

Latest Information Update: 28 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Numab
  • Developer Intarcia Therapeutics; Numab
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action CD3 antigen inhibitors; Interleukin 17 inhibitors; Interleukin 5 receptor antagonists; Th17 cell inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Autoimmune disorders; Diabetes mellitus; Inflammation; Obesity

Most Recent Events

  • 28 Oct 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in Switzerland
  • 28 Apr 2019 No recent reports of development identified for research development in Diabetes-mellitus in Switzerland
  • 28 Apr 2019 No recent reports of development identified for research development in Obesity in Switzerland

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top